These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 21705072)

  • 21. Mitochondrial pathophysiology and type 2 diabetes mellitus.
    Garcia-Roves PM
    Arch Physiol Biochem; 2011 Jul; 117(3):177-87. PubMed ID: 21671709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting type 2 diabetes.
    Schwanstecher C; Schwanstecher M
    Handb Exp Pharmacol; 2011; (203):1-33. PubMed ID: 21484565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Metabolic and cardiovascular effects of physical activity, exercise and fitness in patients with type 2 diabetes].
    Blüher M; Zimmer P
    Dtsch Med Wochenschr; 2010 May; 135(18):930-4. PubMed ID: 20425681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function.
    Mudaliar S; Henry RR
    Am J Med; 2010 Mar; 123(3 Suppl):S19-27. PubMed ID: 20206728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type-2 diabetes: Current understanding and future perspectives.
    Pandey A; Chawla S; Guchhait P
    IUBMB Life; 2015 Jul; 67(7):506-13. PubMed ID: 26177573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic flexibility in metabolic regulation: disease cause and prevention?
    Kirchner H; Osler ME; Krook A; Zierath JR
    Trends Cell Biol; 2013 May; 23(5):203-9. PubMed ID: 23277089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The genetics and pathophysiology of type II and gestational diabetes.
    Csorba TR; Edwards AL
    Crit Rev Clin Lab Sci; 1995; 32(5-6):509-50. PubMed ID: 8561892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights.
    Vaag A
    Dan Med Bull; 1999 Jun; 46(3):197-234. PubMed ID: 10421979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
    Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
    Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fetal programming of type 2 diabetes--intrauterine growth retardation (IUGR) as risk factor?].
    Eberle C
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():76-82. PubMed ID: 21595150
    [No Abstract]   [Full Text] [Related]  

  • 31. Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes.
    Tsuchiyama N; Takamura T; Ando H; Sakurai M; Shimizu A; Kato K; Kurita S; Kaneko S
    Diabetes Care; 2007 Oct; 30(10):2583-7. PubMed ID: 17644622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Energy restriction prevents the development of type 2 diabetes in Zucker diabetic fatty rats: coordinated patterns of gene expression for energy metabolism in insulin-sensitive tissues and pancreatic islets determined by oligonucleotide microarray analysis.
    Colombo M; Kruhoeffer M; Gregersen S; Agger A; Jeppesen P; Oerntoft T; Hermansen K
    Metabolism; 2006 Jan; 55(1):43-52. PubMed ID: 16324918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of severe hyperglycaemia in pregnancy and early overfeeding on islet development and insulin resistance].
    Zeng CJ; Zhang L; Yang HX
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):658-63. PubMed ID: 21092544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B.
    Walz HA; Härndahl L; Wierup N; Zmuda-Trzebiatowska E; Svennelid F; Manganiello VC; Ploug T; Sundler F; Degerman E; Ahrén B; Holst LS
    J Endocrinol; 2006 Jun; 189(3):629-41. PubMed ID: 16731793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Physical exercise and insulin resistance: from muscle metabolic physiopathology to therapeutics].
    Bordenave S; Aguer C; Kitzmann M; Mercier J
    J Soc Biol; 2007; 201(2):149-54. PubMed ID: 17978747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance.
    Pagel-Langenickel I; Bao J; Pang L; Sack MN
    Endocr Rev; 2010 Feb; 31(1):25-51. PubMed ID: 19861693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrauterine Programming of Diabetes and Adiposity.
    Tomar AS; Tallapragada DS; Nongmaithem SS; Shrestha S; Yajnik CS; Chandak GR
    Curr Obes Rep; 2015 Dec; 4(4):418-28. PubMed ID: 26349437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding type 2 diabetes: from genetics to epigenetics.
    Raciti GA; Longo M; Parrillo L; Ciccarelli M; Mirra P; Ungaro P; Formisano P; Miele C; Béguinot F
    Acta Diabetol; 2015 Oct; 52(5):821-7. PubMed ID: 25841587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic programming in the pathogenesis of insulin resistance.
    Devaskar SU; Thamotharan M
    Rev Endocr Metab Disord; 2007 Jun; 8(2):105-13. PubMed ID: 17657604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mechanisms of action for treatments of type 2 diabetes.
    Leahy JJ
    Diabetes Educ; 2007; 33 Suppl 5():101S-4S. PubMed ID: 17548896
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.